On September 25-28 2016, the Division of Occupation and Environmental Medicine at the Icahn School of Medicine at Mount Sinai will host MANGANESE2016, an international conference on the neurotoxicity and prevention of adverse manganese health effects.
Manganese is a metal used in the production of steel and other metal manufacturing. Industrial use of manganese sometimes releases high concentrations of it in the air via dust or fumes, making workers in these industries and residents of these areas especially susceptible to manganese-related health conditions. Read more
Kidney transplantation is the most common type of organ transplant surgery in the United States with over 17,000 kidney transplantations performed in 2014, according to the National Kidney Foundation. However, long-term survival still remains a challenge. While there is no actual crystal ball to predict whether a transplanted kidney will later develop fibrosis – a chronic injury that is a major cause of allograft loss after the first year – a team of researchers, led by Mount Sinai’s Barbara Murphy, MD, System Chair, Department of Medicine, Murray M. Rosenberg Professor of Medicine, Dean for Clinical Integration and Population Health, has identified a panel of 13 genes that does just that. These recently discovered 13 genes are highly predictive of decline in renal function and eventual loss of transplanted kidneys. Read more
Medical Treatment at Home
An innovative program being run by the Mount Sinai Health System has shown that certain acute-care patients who choose to be treated at home rather than in a hospital are not only more satisfied with their care but also have lower medical costs and fewer medical complications.
These findings come amid the halfway point of a three-year plan that was launched by Mount Sinai in November 2014 after receiving a $9.6 million Health Care Innovation Award from the federal Centers for Medicare and Medicaid Services (CMS) to create a unique “hospital at home” program.
Known as the Mobile Acute Care Team (MACT), the program illustrates Mount Sinai’s commitment to being on the cutting edge of the way medicine will be practiced and creating an innovative health care system for the future, one that emphasizes outpatient, ambulatory, and home-based care with remote monitoring capabilities. The award further highlights Mount Sinai’s role as a pioneer in developing a new clinical and financial reimbursement model for patients with acute illnesses. Read more
Guest post by Ilana Kersch, MS RD CDN, Senior Dietitian at the Mount Sinai Hospital. Ilana works as part of the inpatient liver transplant team in conjunction with the Recanati Miller Transplant Institute, and provides nutrition care for patients pre- and post-hepatobiliary surgery.
In recent decades, non-alcoholic fatty liver disease (NAFLD) has become an important cause of liver disease in the US due to its association with rising prevalence of obesity and type 2 diabetes. It is estimated that approximately 30% of the US population now has some degree of non-alcoholic fatty liver, and ~2- 5% of the population have fatty liver which has progressed to non-alcoholic steatohepatitis (NASH). If untreated, NAFLD and NASH can progress to liver cirrhosis and malignancy, and is quickly becoming a major indication for listing for liver transplant. Read more
Kateri Moore, DVM, left, with graduate students Andreia Gomes and Jeffrey Bernitz
For scientists who study stem cells, the ability to produce hematopoietic stem/progenitor cells (HSPCs) in the lab and then transplant them into patients with blood disorders has been a long-sought-after goal. Recently, the field took a step closer to that milestone when researchers at the Icahn School of Medicine at Mount Sinai identified cells in the embryos and placentas of mice that are actually precursors to HSPCs. Hematopoiesis is the daily process by which the human body generates all of the different types of cells found in the blood and immunological system. Read more
Casey Crump, MD, PhD
Physical fitness in late adolescence may reduce the risk of developing type 2 diabetes later in life, according to a new study from the Icahn School of Medicine at Mount Sinai that appeared online in the March 8, 2016, issue of the Annals of Internal Medicine.
Researchers—led by Casey Crump, MD, PhD, Vice Chair for Research in the Department of Family Medicine and Community Health at Icahn School of Medicine at Mount Sinai—evaluated data on the aerobic capacity of 1.5 million males who were military conscripts in Sweden between 1969 and 1997. The scientists then compared the men’s aerobic capacity to their medical diagnoses that were made between 1987 and 2012, when the men were a maximum age of 62. Read more
Guest post by Alysia Johansson MS RD CDN, Clinical Nutrition Coordinator at The Mount Sinai Hospital. Alysia has been at Mount Sinai since 2011 where she works as part of the interdisciplinary Cardiothoracic ICU team. Alysia also coordinates malnutrition efforts for the Clinical Nutrition Department and will be presenting at an upcoming conference on April 21 2016 at The Mount Sinai Hospital, Malnutrition: Implementing Strategies for Medical Nutrition Therapy.
Malnutrition has been recognized as a problem in hospitalized patients for over 40 years. Malnutrition is any disorder of nutrition resulting from unbalanced or insufficient diet, increased needs, or impaired absorption, utilization, or excretion of nutrients – all in the presence or absence of inflammation. Malnutrition contributes to a multitude of poor patient outcomes including decreased function and quality of life, decreased wound healing, anemia, increased risk of infection, increased risk for developing pressure ulcers, increased risk of surgical complications, increased mortality, increased frequency of hospital admissions and increased length of hospital stay. Aside from being detrimental to care, all of these outcomes lead to higher healthcare costs. For these reasons, it is imperative that clinicians be aware of the signs of malnutrition, and take proper measures to enhance the nutritional status of their patients. Read more
Investigators, from left, Samir Parekh, MD; and Deepak Perumal, PhD
Research into a novel treatment that could help extend the lives of patients with multiple myeloma—a disease in which cancerous blood cells proliferate in the bone marrow—is being advanced by scientists at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, who recently identified a new drug target called ARK5.
The Mount Sinai scientists discovered that when ARK5 is targeted simultaneously with CDK4, a pathway widely known to have a role in inhibiting multiple myeloma, the results were extremely effective in causing cell death. Their findings were published in the March 15, 2016, issue of the journal Cancer Research. Read more
Ashish Atreja, MD, MPH, center, with Bruce Darrow, MD, PhD, Associate Professor of Medicine (Cardiology) and Chief Medical Information Officer, Mount Sinai Health System, left, and Jagat Narula, MD, PhD, Associate Dean for Global Affairs, the Philip J. and Harriet L. Goodhart Professor of Medicine, and editorial board member of Mount Sinai’s upcoming Journal of Digital Medicine Evidence.
A new knowledge and data-sharing platform created by researchers at the Mount Sinai Health System is designed to help physicians weed through the thousands of mobile health apps that enter the market each year and identify the ones that successfully improve patient health. Called NODE Health (Network of Digital Evidence in Health), the platform was created by researchers at Mount Sinai’s AppLab, which is led by Ashish Atreja, MD, MPH, Chief Technology Innovation and Engagement Officer in the Department of Medicine, and Assistant Professor of Medicine (Gastroenterology). NODEHealth.org will provide physicians and other health care providers with an evidence-based review process and data-sharing network that is similar to ClinicalTrials.gov, enabling them to compare studies from around the world to find the health care apps that work best for their specialized needs. Read more
The AP (Artificial Pancreas) system runs an algorithm on a smartphone that communicates with an insulin pump and an implanted glucose sensor.
Research under way at the Icahn School of Medicine at Mount Sinai is revolutionizing the management of type 1 diabetes by using novel technology that serves as an artificial pancreas and automatically enables patients to achieve more stable glucose levels 24 hours a day.
Led by Carol Levy, MD, Associate Professor of Medicine (Endocrinology, Diabetes and Bone Disease), the Icahn School of Medicine is one of nine U.S. and European sites participating in the research, and sharing a $12.7 million grant from the National Institutes of Health. Dr. Levy is one of the study’s lead investigators. Read more